{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:28:00Z","timestamp":1793831280890,"version":"4.6.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jacasi.2022.08.015","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:08:36Z","timestamp":1668557316000},"page":"653-665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Lipoprotein(a) and Cardiovascular Disease in Chinese Population"],"prefix":"10.1016","volume":"2","author":[{"given":"Jian-Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Sheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuyi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoquan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yida","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanlin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naqiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacasi.2022.08.015_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"10.1016\/j.jacasi.2022.08.015_bib2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacasi.2022.08.015_bib3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A\u00a0new serum type system in man\u2014the Lp system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"key":"10.1016\/j.jacasi.2022.08.015_bib4","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.numecd.2016.07.004","article-title":"Lp(a) and cardiovascular risk: Investigating the hidden side of the moon","volume":"26","author":"Bucci","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacasi.2022.08.015_bib5","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacasi.2022.08.015_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1752-8062.2010.00238.x","article-title":"Enigmatic role of lipoprotein(a) in cardiovascular disease","volume":"3","author":"Anuurad","year":"2010","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jacasi.2022.08.015_bib7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.amjcard.2016.06.020","article-title":"Relation of plasma lipoprotein(a) to subclinical coronary plaque volumes, three-vessel and left main coronary disease, and severe coronary stenoses in apparently healthy African-Americans with a family history of early-onset coronary artery disease","volume":"118","author":"Kral","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib8","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacasi.2022.08.015_bib9","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2022.08.015_bib10","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish familial hypercholesterolemia cohort study)","volume":"135","author":"P\u00e9rez de Isla","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2022.08.015_bib11","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2022.08.015_bib12","article-title":"Correlations between lipoprotein(a) gene polymorphisms and calcific aortic valve disease and coronary heart disease in Han Chinese","volume":"48","author":"Dong","year":"2020","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.jacasi.2022.08.015_bib13","first-page":"1263","article-title":"Progress in search for traditional Chinese medicine treating prostate cancer via androgen receptor signaling regulation","volume":"33","author":"Cao","year":"2017","journal-title":"Chin J Clin Pharmacol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on Lipoprotein(a): A call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacasi.2022.08.015_bib15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A\u00a0test in context: Lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib16","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated Lp(a) mass levels and patient thresholds in 532,359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.cca.2018.06.004","article-title":"Establishing age and sex dependent upper reference limits for the plasma lipoprotein (a) in a Chinese health check-up population and according to its relative risk of primary myocardial infarction","volume":"484","author":"Cui","year":"2018","journal-title":"Clinica Chimica Acta"},{"key":"10.1016\/j.jacasi.2022.08.015_bib18","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1172\/JCI117263","article-title":"Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in 3 ethnic groups. Evidence for no common \u201cnull\u201d allele at the apo(a) locus","volume":"93","author":"Gaw","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacasi.2022.08.015_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce Lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib20","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1194\/jlr.P091009","article-title":"A\u00a0genome-wide association study on lipoprotein (a) levels and coronary artery disease severity in a Chinese population","volume":"60","author":"Liu","year":"2019","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacasi.2022.08.015_bib21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacasi.2022.08.015_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105812","article-title":"Lipoprotein(a): knowns, unknowns and uncertainties","volume":"173","author":"Ruscica","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jacasi.2022.08.015_bib23","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehx033","article-title":"Lipoprotein(a): the revenant","volume":"38","author":"Gencer","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2022.08.015_bib24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2019.10.044","article-title":"Interaction of lipoprotein(a) with low-density lipoprotein cholesterol on first incident acute myocardial infarction","volume":"501","author":"Hu","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jacasi.2022.08.015_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2019.07.025","article-title":"Serum lipoprotein (a) is associated with increased risk of stroke in Chinese adults: a prospective study","volume":"289","author":"Zhang","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacasi.2022.08.015_bib28","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1161\/STROKEAHA.119.026872","article-title":"Causal effect of Lp(a) [Lipoprotein(a)] level on ischemic stroke and alzheimer disease: A mendelian randomization study","volume":"50","author":"Pan","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.jacasi.2022.08.015_bib29","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib30","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamacardio.2018.3798","article-title":"Association of mild to moderate aortic valve stenosis progression with higher lipoprotein(a) and oxidized phospholipid levels: Secondary analysis of a randomized clinical trial","volume":"3","author":"Capoulade","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib31","first-page":"133","article-title":"Association of serum lipoprotein(a) level with the severity and prognosis of calcific aortic valve stenosis: a Chinese cohort study","volume":"17","author":"Liu","year":"2020","journal-title":"J\u00a0Geriatr Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2019.10.010","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia","volume":"291","author":"Cao","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacasi.2022.08.015_bib33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2018.12.022","article-title":"Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk In Communities study","volume":"282","author":"Saeed","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacasi.2022.08.015_bib34","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2022.08.015_bib35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12933-020-01083-8","article-title":"Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study","volume":"19","author":"Zhang","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2022.08.015_bib37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0021-9150(02)00026-6","article-title":"Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study","volume":"163","author":"Luc","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacasi.2022.08.015_bib38","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1136\/heartjnl-2020-316586","article-title":"Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease","volume":"106","author":"Liu","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.jacasi.2022.08.015_bib39","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.291.18.2204","article-title":"Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring","volume":"29","author":"Lloyd-Jones","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacasi.2022.08.015_bib40","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1161\/CIRCULATIONAHA.107.705202","article-title":"Parental occurrence of premature cardiovascular disease predicts increased coronary artery and abdominal aortic calcification in the Framingham Offspring and Third Generation cohorts","volume":"116","author":"Parikh","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2022.08.015_bib41","first-page":"1263","article-title":"2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib42","first-page":"1","article-title":"2016 Chinese guideline for the management of dyslipidemia in adults","volume":"15","year":"2018","journal-title":"J\u00a0Geriatr Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib43","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib44","article-title":"Predicting cardiovascular outcomes by baseline lipoprotein(a) concentrations: a large cohort and long-term follow-up study on real-world patients receiving percutaneous coronary intervention","volume":"9","author":"Liu","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacasi.2022.08.015_bib45","doi-asserted-by":"crossref","first-page":"212","DOI":"10.21037\/atm.2020.01.38","article-title":"Association between lipoprotein(a) concentration and the risk of stroke in the Chinese Han population: a retrospective case-control study","volume":"8","author":"Fu","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jacasi.2022.08.015_bib46","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jacc.2021.12.018","article-title":"Lipoprotein(a) and coronary calcium: Clinical management and potential design of primary prevention trials","volume":"79","author":"Tsimikas","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.11.010","article-title":"Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-Norfolk prospective population study","volume":"256","author":"Perrot","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacasi.2022.08.015_bib48","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1194\/jlr.M008961","article-title":"Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy","volume":"51","author":"Nicholls","year":"2010","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacasi.2022.08.015_bib49","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2022.08.015_bib50","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/ NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of Cardiology\/ American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib51","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global Health Outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib52","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jacasi.2022.08.015_bib53","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacasi.2022.08.015_bib54","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacasi.2022.08.015_bib55","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2016.09.010","article-title":"Effect of alirocumab on lipoprotein(a) over\u00a0\u22651.5 years (from the phase 3 ODYSSEY program)","volume":"119","author":"Gaudet","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib57","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacasi.2022.08.015_bib58","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2022.08.015_bib59","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2019.06.896","article-title":"Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: pooled analysis of alirocumab phase 3 trials","volume":"288","author":"Ray","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacasi.2022.08.015_bib60","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2022.08.015_bib61","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LP(A) variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: A mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib62","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacasi.2022.08.015_bib63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ecl.2015.09.003","article-title":"Lipoprotein apheresis","volume":"45","author":"Moriarty","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.jacasi.2022.08.015_bib64","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","article-title":"Recommendations for the use of LDL apheresis","volume":"198","author":"Thompson","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacasi.2022.08.015_bib65","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11789-017-0089-9","article-title":"The German lipoprotein apheresis registry (GLAR) - almost 5 years on","volume":"12","author":"Schettler","year":"2017","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.jacasi.2022.08.015_bib66","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1567-5688(09)71819-7","article-title":"Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study","volume":"10","author":"Stefanutti","year":"2009","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jacasi.2022.08.015_bib67","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.jacasi.2022.08.015_bib68","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/eurheartj\/ehx178","article-title":"Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial","volume":"38","author":"Khan","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2022.08.015_bib69","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2018.11.011","article-title":"RNA therapy: Are we using the right molecules?","volume":"196","author":"Yu","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jacasi.2022.08.015_bib70","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): 2 randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2022.08.015_bib71","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacasi.2022.08.015_bib72","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacasi.2022.08.015_bib73","first-page":"651","article-title":"Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia","volume":"8","author":"Bell","year":"2012","journal-title":"Vasc Health Risk Manag"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374722002320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374722002320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T09:58:14Z","timestamp":1757411894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772374722002320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2772374722002320"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2022.08.015","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) and Cardiovascular Disease in Chinese Population","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2022.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}